Press releases.

Press releases 2020

Press releases 2020

Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor

December 29th 2020

Immutep Upscales Efti Manufacturing

December 16th 2020

Immutep Operational Update

December 15th 2020

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

December 9th 2020

Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast Cancer

December 9th 2020

Immutep Announces Expansion of TACTI-002 Collaboration Trial

November 18th 2020

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

November 18th 2020

Immutep Announces Australian Patent Grant for IMP701 Antibody

November 9th 2020

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

November 9th 2020

Immutep’s TACTI-002 Data To Be Presented At Society For Immunotherapy Of Cancer 2020 Annual Meeting

November 2nd 2020

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

October 29th 2020

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

October 23rd 2020

Immutep Granted European Patent for IMP761

October 21st 2020

Immutep Activities Report for the First Quarter of Fiscal Year 2021

October 21st 2020

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

October 19th 2020

Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study

September 17th 2020

Immutep Reports Improving Results from INSIGHT-004 Trial

September 17th 2020

Immutep and Monash University Receive Grant Funding for LAG-3 Project

August 31st 2020

New Data From Immutep’s Efti To Be Presented At ESMO

August 26th 2020

Immutep Completes Recruitment for Stage 1 of Part B in TACTI-002 Study

August 18th 2020

Immutep Issues Newsletter Update to Shareholders

August 17th 2020

Immutep Granted United States Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

August 11th 2020

Immutep Quarterly Activities Report

July 23rd 2020

Immutep Announces United States Patent Grant for IMP701 Antibody

July 14th 2020

Immutep Completes Recruitment for Part A Of Phase II TACTI-002 Study

June 29th 2020

Immutep Receives A$1,437,826 R&D Tax Incentive

June 22nd 2020

Immutep Announces Improving Data from the Phase II TACTI-002 Study

May 31st 2020

Immutep Reports First Results from INSIGHT-004 Study

May 31st 2020

Immutep Receives US$2.4 Million R&D Tax Incentive from French Government

May 28th 2020

Immutep Global Webcast to Present New Data from 2020 ASCO Annual Meeting

May 26th 2020

Immutep Granted Japanese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination

May 7th 2020

Immutep Announces First INSIGHT-004 Data and New TACTI-002 Data to be Included in Poster Presentations During the ASCO 2020 Annual Meeting

April 29th 2020

Immutep Reports Positive Phase II TACTI-002 Data

April 28th 2020

Enrollment completed for the INSIGHT-004 Study

April 21st 2020

Immutep Quarterly Activities Report

April 20th 2020

Immutep Advances Cell Line Development for IMP761

April 15th 2020

Immutep TACTI-002 Data Presentation at the AACR Virtual Annual Meeting 2020

April 14th 2020

Immutep’s Partner, EOC Pharma, Continues to Advance Efti in Breast Cancer

April 8th 2020

Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020

March 24th 2020

Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti

March 19th 2020

Immutep Receives Second IND Approval for Efti from US FDA

March 9th 2020

Immutep Reports Positive TACTI-002 Data

February 19th 2020

Immutep to Present TACTI-002 Interim Data at German Cancer Congress

February 4th 2020

Immutep Activities Report

January 29th 2020

Immutep Expands Part C of TACTI-002 Due to Positive Data

January 9th 2020